Comparative evaluation of the new FDA approved THxID™-BRAF test with high resolution melting and sanger sequencing

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Marchant, Julie ^a   Mange, Alain ^a,b   Larrieux, Marion ^a   Costes, Valérie ^a,b   Solassol, Jérôme ^a,b  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b UNIV MONTPELLIER   (France)

Author keywords

BRAF; Detection; Melanoma; V600 mutations

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; DIAGNOSTIC KIT;

ADULT; ARTICLE; B RAF KINASE GENE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MOLECULAR DIAGNOSTICS; MUTATIONAL ANALYSIS; SANGER SEQUENCING; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; WILD TYPE; COMPARATIVE STUDY; DIAGNOSTIC KIT; DNA SEQUENCE; FOOD AND DRUG ADMINISTRATION; GENETICS; MELANOMA; MIDDLE AGED; MUTATION; PROCEDURES; REPRODUCIBILITY; UNITED STATES;

FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; SEQUENCE ANALYSIS, DNA; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84905822400     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-519     Document Type: Article

References (36)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63(1):11-30. 10.3322/caac.21166, 23335087.
2. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001, 19(16):3635-3648.
3. Eggermont AM, Spatz A, Robert C. Cutaneous melanoma. Lancet 2014, 383(9919):816-827. 10.1016/S0140-6736(13)60802-8, 24054424.
4. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA,. BRIM-3 Study Group Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364(26):2507-2516. 10.1056/NEJMoa1103782, 3549296, 21639808, BRIM-3 Study Group.
5. Lee JH, Choi JW, Kim YS. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol 2011, 164(4):776-784. 10.1111/j.1365-2133.2010.10185.x, 21166657.
6. Rubinstein JC, Sznol M, Pavlick AC, Ariyan S, Cheng E, Bacchiocchi A, Kluger HM, Narayan D, Halaban R. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med 2010, 8:67. 10.1186/1479-5876-8-67, 2917408, 20630094.
7. Amanuel B, Grieu F, Kular J, Millward M, Iacopetta B. Incidence of BRAF p. Val600Glu and p. Val600Lys mutations in a consecutive series of 183 metastatic melanoma patients from a high incidence region. Pathology 2012, 44(4):357-359. 10.1097/PAT.0b013e3283532565, 22614711.
8. Menzies AM, Haydu LE, Visintin L, Carlino MS, Howle JR, Thompson JF, Kefford RF, Scolyer RA, Long GV. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res 2012, 18(12):3242-3249. 10.1158/1078-0432.CCR-12-0052, 22535154.
9. McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, Ribas A, Hogg D, Hamid O, Ascierto PA, Garbe C, Testori A, Maio M, Lorigan P, Lebbe´ C, Jouary T, Schadendorf D, O'Day SJ, Kirkwood JM, Eggermont AM, Dre´no B, Sosman JA, Flaherty KT, Yin M, Caro I, Cheng S, Trunzer K, Hauschild A. Safety and efficacy of vemurafenib in BRAF (V600E) and BRAF (V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014, 15(3):323-332. 10.1016/S1470-2045(14)70012-9, 24508103.
10. GlaxoSmithKline Two New GSK Oral Oncology Treatments B-iTRdcatfM-iMTtt, Approved by FDA as Single-Agent Therapies [media release] 2013, http://www.gsk.com, GlaxoSmithKline.
11. Newton CR, Graham A, Heptinstall LE, Powell SJ, Summers C, Kalsheker N, Smith JC, Markham AF. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res 1989, 17(7):2503-2516. 10.1093/nar/17.7.2503, 317639, 2785681.
12. Srinivasan M, Sedmak D, Jewell S. Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am J Pathol 2002, 161(6):1961-1971. 10.1016/S0002-9440(10)64472-0, 1850907, 12466110.
13. Brown LD, Cat TT, DasGupta A. Interval Estimation for a Binomial Proportion. Stat Sci 2001, 16(2):101-133.
14. Gonzalez D, Fearfield L, Nathan P, Taniere P, Wallace A, Brown E, Harwood C, Marsden J, Whittaker S. BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel. Br J Dermatol 2013, 168(4):700-707. 10.1111/bjd.12248, 23360189.
15. Didelot A, Le Corre D, Luscan A, Cazes A, Pallier K, Emile JF, Laurent-Puig P, Blons H. Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples. Exp Mol Pathol 2012, 92(3):275-280. 10.1016/j.yexmp.2012.03.001, 22426079.
16. Huang T, Zhuge J, Zhang WW. Sensitive detection of BRAF V600E mutation by Amplification Refractory Mutation System (ARMS)-PCR. Biomark Res 2013, 1(1):3. 10.1186/2050-7771-1-3, 3776245, 24252159.
17. Pichler M, Balic M, Stadelmeyer E, Ausch C, Wild M, Guelly C, Bauernhofer T, Samonigg H, Hoefler G, Dandachi N. Evaluation of high-resolution melting analysis as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumors. J Mol Diagn 2009, 11(2):140-147. 10.2353/jmoldx.2009.080100, 2665863, 19213871.
18. Ihle MA, Fassunke J, Konig K, Grunewald I, Schlaak M, Kreuzberg N, Tietze L, Schildhaus HU, Buttner R, Merkelbach-Bruse S. Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p. V600E and non-p. V600E BRAF mutations. BMC Cancer 2014, 14:13. 10.1186/1471-2407-14-13, 3893431, 24410877.
19. McCourt CM, McArt DG, Mills K, Catherwood MA, Maxwell P, Waugh DJ, Hamilton P, O'Sullivan JM, Salto-Tellez M. Validation of next generation sequencing technologies in comparison to current diagnostic gold standards for BRAF, EGFR and KRAS mutational analysis. PLoS One 2013, 8(7):e69604. 10.1371/journal.pone.0069604, 3724913, 23922754.
20. Tuononen K, Maki-Nevala S, Sarhadi VK, Wirtanen A, Ronty M, Salmenkivi K, Andrews JM, Telaranta-Keerie AI, Hannula S, Lagstrom S, Ellonen P, Knuuttila A, Knuutila S. Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS. Genes Chromosomes Cancer 2013, 52(5):503-511. 10.1002/gcc.22047, 23362162.
21. Colomba E, Helias-Rodzewicz Z, Von Deimling A, Marin C, Terrones N, Pechaud D, Surel S, Cote JF, Peschaud F, Capper D, Blons H, Zimmermann U, Clerici T, Saiag P, Emile JF. Detection of BRAF p. V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. J Mol Diagn 2013, 15(1):94-100. 10.1016/j.jmoldx.2012.09.001, 23159108.
22. Heideman DA, Lurkin I, Doeleman M, Smit EF, Verheul HM, Meijer GA, Snijders PJ, Thunnissen E, Zwarthoff EC. KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA. J Mol Diagn 2012, 14(3):247-255. 10.1016/j.jmoldx.2012.01.011, 22425762.
23. Carbonell P, Turpin MC, Torres-Moreno D, Molina-Martinez I, Garcia-Solano J, Perez-Guillermo M, Conesa-Zamora P. Comparison of allelic discrimination by dHPLC, HRM, and TaqMan in the detection of BRAF mutation V600E. J Mol Diagn 2011, 13(5):467-473. 10.1016/j.jmoldx.2011.03.009, 3157612, 21708284.
24. Lade-Keller J, Romer KM, Guldberg P, Riber-Hansen R, Hansen LL, Steiniche T, Hager H, Kristensen LS. Evaluation of BRAF mutation testing methodologies in formalin-fixed, paraffin-embedded cutaneous melanomas. J Mol Diagn 2013, 15(1):70-80. 10.1016/j.jmoldx.2012.08.003, 23159593.
25. Lopez-Rios F, Angulo B, Gomez B, Mair D, Martinez R, Conde E, Shieh F, Vaks J, Langland R, Lawrence HJ, Lawrence HJ, de Castro DG. Comparison of testing methods for the detection of BRAF V600E mutations in malignant melanoma: pre-approval validation study of the companion diagnostic test for vemurafenib. PLoS One 2013, 8(1):e53733. 10.1371/journal.pone.0053733, 3542342, 23326492.
26. Qu K, Pan Q, Zhang X, Rodriguez L, Zhang K, Li H, Ho A, Sanders H, Sferruzza A, Cheng SM, Nguyen D, Jones D, Waldman F. Detection of BRAF V600 mutations in metastatic melanoma: comparison of the Cobas 4800 and Sanger sequencing assays. J Mol Diagn 2013, 15(6):790-795. 10.1016/j.jmoldx.2013.07.003, 23994118.
27. Anderson S, Bloom KJ, Vallera DU, Rueschoff J, Meldrum C, Schilling R, Kovach B, Lee JR, Ochoa P, Langland R, Halait H, Lawrence HJ, Dugan MC. Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma. Arch Pathol Lab Med 2012, 136(11):1385-1391. 10.5858/arpa.2011-0505-OA, 22332713.
28. Halait H, Demartin K, Shah S, Soviero S, Langland R, Cheng S, Hillman G, Wu L, Lawrence HJ. Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma. Diagn Mol Pathol 2012, 21(1):1-8. 10.1097/PDM.0b013e31823b216f, 22306669.
29. Ellison G, Donald E, McWalter G, Knight L, Fletcher L, Sherwood J, Cantarini M, Orr M, Speake G. A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples. J Exp Clin Cancer Res 2010, 29:132. 2988723, 20925915.
30. Hamfjord J, Stangeland AM, Skrede ML, Tveit KM, Ikdahl T, Kure EH. Wobble-enhanced ARMS method for detection of KRAS and BRAF mutations. Diagn Mol Pathol 2011, 20(3):158-165. 10.1097/PDM.0b013e31820b49e2, 21817902.
31. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012, 366(8):707-714. 10.1056/NEJMoa1112302, 3724515, 22356324.
32. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D,. METRIC Study Group Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012, 367(2):107-114. 10.1056/NEJMoa1203421, 22663011, METRIC Study Group.
33. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH, Kaempgen E, Marti´n-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, Haney P, Mirakhur B, Guckert ME, Goodman V, Chapman PB. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012, 380(9839):358-365. 10.1016/S0140-6736(12)60868-X, 22735384.
34. Jordan EJ, Kelly CM. Vemurafenib for the treatment of melanoma. Expert Opin Pharmacother 2012, 13(17):2533-2543. 10.1517/14656566.2012.737780, 23094782.
35. Yang H, Higgins B, Kolinsky K, Packman K, Go Z, Iyer R, Kolis S, Zhao S, Lee R, Grippo JF, Schostack K, Simcox ME, Heimbrook D, Bollag G, Su F. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res 2010, 70(13):5518-5527. 10.1158/0008-5472.CAN-10-0646, 20551065.
36. Ballantyne AD, Garnock-Jones KP. Dabrafenib: first global approval. Drugs 2013, 73(12):1367-1376. 10.1007/s40265-013-0095-2, 23881668.